Anafranil tablets are taken by mouth, with or without food, for conditions such as obsessive-compulsive disorder, depression, and panic disorder. They contain clomipramine hydrochloride, a tricyclic antidepressant that increases serotonin and norepinephrine activity in the brain.
Anafranil contains clomipramine hydrochloride. Clomipramine is the generic name of the active compound, while Anafranil is the product name used for this formulation. It belongs to the tricyclic antidepressant class.
Anafranil tablets are taken orally. The prescribed daily amount depends on the condition being treated, the tablet strength, age, liver function, other medicines, and the person’s response. There is no single amount suitable for every patient.
Treatment commonly begins cautiously and increases in stages. Gradual titration allows the body to adjust to sedation, nausea, dizziness, dry mouth, changes in blood pressure, and other early effects. The prescriber may later simplify the schedule once a stable daily amount has been reached.
Clomipramine is metabolized in the liver, with active metabolites contributing to its clinical effects. Age, liver impairment, smoking status, and interacting medicines can alter exposure. A delayed increase in side effects can occur after a dose change because the medicine and its metabolites do not leave the body immediately.
One practical point is easy to miss: constipation can become significant with tricyclic treatment. Regular fluids, fibre when appropriate, and early attention to reduced bowel movements can prevent a minor symptom from becoming painful or medically serious.
Anafranil contains clomipramine hydrochloride. Clomipramine is the generic name of the active compound, while Anafranil is the product name used for this formulation. It belongs to the tricyclic antidepressant class.
Clomipramine has a strong effect on serotonin reuptake and a further effect on norepinephrine reuptake. This combination helps regulate signalling between nerve cells involved in obsessive thoughts, compulsive behaviours, mood, fear responses, and anxiety. The Canadian product monograph and regulatory information for clomipramine describe oral tablets used within a supervised antidepressant treatment plan [1].
Clomipramine hydrochloride is the hydrochloride salt of clomipramine. After oral administration, the body converts and distributes the medicine through the bloodstream before it reaches central nervous system tissues.
Its pharmacological actions extend beyond serotonin and norepinephrine transporters. Tricyclic antidepressants can also affect muscarinic, histamine, and adrenergic receptors. These secondary actions help explain dry mouth, constipation, drowsiness, blurred vision, postural dizziness, and changes in heart rate.
Clomipramine blocks the reuptake transporters responsible for removing serotonin and norepinephrine from the synaptic cleft. More of these neurotransmitters remain available between nerve cells, allowing repeated signals to influence mood, anxiety, fear processing, and repetitive behaviour circuits.
The serotonin effect is especially relevant to OCD and panic disorder. Norepinephrine activity contributes to alertness, attention, and mood regulation. These effects do not appear instantly because downstream changes in receptor sensitivity and neural networks take time.
Anafranil also binds to several other receptors. Histamine H1 blockade may cause sedation and increased appetite. Muscarinic receptor blockade may lead to dry mouth, constipation, urinary difficulty, sweating changes, and blurred near vision. Alpha-adrenergic effects can contribute to dizziness when standing.
This receptor profile distinguishes clomipramine from selective serotonin reuptake inhibitors, which focus more narrowly on serotonin transport. It also explains why clomipramine may help when serotonin-based treatment is needed, while producing more anticholinergic and cardiovascular effects than many newer antidepressants.
The World Health Organization describes antidepressant treatment as one component of care for depressive disorders and selected anxiety-related conditions, with monitoring needed during initiation and dose changes [3].
Anafranil is used mainly for obsessive-compulsive disorder, also called OCD. It may also be prescribed for depressive illness and panic disorder when a tricyclic approach is clinically appropriate. The choice depends on symptoms, previous treatment response, medical history, and interaction risks.
OCD involves persistent intrusive thoughts, images, or urges and repetitive behaviours or mental acts performed to reduce distress. Clomipramine can reduce the intensity and frequency of these symptoms over time. It does not remove the need for behavioural treatment; exposure and response prevention remains a central psychological therapy for OCD.
Depression may involve low mood, loss of interest, sleep changes, reduced concentration, guilt, slowed thinking, or thoughts of death. Anafranil may be considered when depressive symptoms require antidepressant treatment, although its side-effect profile means that clinicians often assess other options first.
Panic disorder involves recurrent panic attacks and concern about further attacks or their consequences. Clomipramine can reduce panic frequency and anticipatory anxiety after gradual dose adjustment. Early activation, nausea, sleep disturbance, or increased anxiety can occur before the full therapeutic response develops.
| Clinical use | Treatment goal | Typical response pattern |
|---|---|---|
| OCD | Reduce obsessions and compulsions | Improvement usually develops gradually over several weeks |
| Depression | Improve mood, interest, sleep, and concentration | Mood changes may appear before full functional recovery |
| Panic disorder | Reduce panic attacks and anticipatory fear | Early anxiety may settle as treatment continues |
The National Institute for Health and Care Excellence recommends structured psychological treatment and antidepressant strategies for OCD, with treatment selection guided by severity, response, and tolerability [2]. Prescribing practice in Canada also weighs the medicine’s anticholinergic and cardiac effects before selecting it for long-term use.
Several everyday mistakes reduce tolerability or make treatment seem ineffective:
Crushing or chewing is not appropriate for every tablet formulation. The exact handling instructions depend on the formulation supplied and the prescriber’s directions; altered tablets may change how the dose is released or tolerated.
Anafranil is not appropriate for everyone. It should not be used with monoamine oxidase inhibitors or shortly after certain monoamine oxidase inhibitor treatments because of the risk of severe reactions.
This medicine may not be suitable for you if you have heart disease, fainting, seizures, glaucoma, urinary problems, severe liver disease, bipolar disorder, psychosis, thyroid disease, diabetes, significant constipation, or a history of increased eye pressure. It may also be unsuitable if you are pregnant or breastfeeding without an individual medical assessment. Tell your clinician about all medicines and substances you use, especially antidepressants, sedatives, migraine treatments, cough products, and medicines that affect heart rhythm.
Common adverse effects arise from clomipramine’s activity at several receptor types. Dry mouth, constipation, sweating, blurred vision, tremor, nausea, fatigue, sleepiness, increased appetite, and difficulty urinating can occur. Some people experience insomnia or agitation instead of sedation.
Dizziness may be more noticeable when standing up quickly. Clomipramine can lower blood pressure or alter the heart rate, especially during initiation and titration. Older adults may be more sensitive to confusion, falls, constipation, urinary retention, and low sodium.
Sexual dysfunction can include reduced libido, delayed orgasm, or difficulty reaching orgasm. Weight change may occur. These effects should be discussed early because patients sometimes stop treatment without explaining the reason.
Rare but serious reactions include seizures, severe heart rhythm disturbance, fainting, angle-closure glaucoma, urinary retention, severe allergic reactions, and manic symptoms. Antidepressants also require monitoring for new suicidal thinking, severe agitation, or unusual behavioural changes, especially during early treatment and after dose changes.
A small but important practical detail concerns the eyes: sudden eye pain, halos around lights, headache, nausea, and blurred vision can signal acute angle-closure glaucoma. This is an emergency, not a routine dry-mouth effect.
Anafranil can impair sweating and heat tolerance. During hot weather or strenuous exercise, overheating may develop more easily, especially when combined with dehydration or other medicines that reduce sweating.
Clomipramine can interact with medicines that affect serotonin, heart rhythm, blood pressure, seizure threshold, or bleeding. The interaction list should include prescription medicines, non-prescription products, and substances used occasionally.
Medicines that require careful review include:
The Canadian drug product information for clomipramine describes cardiac, neurological, and serotonergic interaction concerns that require medication reconciliation before treatment begins [4]. A pharmacist or prescriber should assess the complete medication list through the online prescribing process, especially when asenapine, apixaban, anagrelide, arsenic trioxide, or artemether is involved.
Serotonin syndrome may involve agitation, confusion, sweating, fever, shivering, diarrhoea, muscle rigidity, tremor, or rapid changes in heart rate. It requires urgent assessment, especially when several serotonin-enhancing medicines are combined.
Clomipramine has a strong serotonin effect but also affects several other receptor systems. Selective serotonin reuptake inhibitors act more selectively on serotonin transport, while serotonin-norepinephrine reuptake inhibitors affect serotonin and norepinephrine with a different receptor profile.
| Approach | Main pharmacology | Common clinical trade-off |
|---|---|---|
| Clomipramine | Tricyclic inhibition of serotonin and norepinephrine reuptake | Useful for OCD, but anticholinergic and cardiac effects require attention |
| Selective serotonin reuptake inhibitor | More selective serotonin reuptake inhibition | Often easier to tolerate, though sexual dysfunction and gastrointestinal effects may occur |
| Serotonin-norepinephrine reuptake inhibitor | Inhibits serotonin and norepinephrine reuptake | May affect blood pressure, sleep, nausea, and anxiety |
For OCD, clomipramine may be considered when an SSRI has not provided enough benefit or has not been tolerated. A clinician may prefer an SSRI first because of the broader safety margin in overdose and the lower burden of anticholinergic effects.
The best option depends on the target symptoms. A medicine that reduces compulsions may still leave severe sedation, constipation, sexual dysfunction, or panic-related activation. Treatment decisions balance symptom relief with daily functioning.
In clinical practice, physicians often describe clomipramine as a medicine that demands patience during the first phase. Nausea, dry mouth, sedation, or restlessness may appear before the desired psychiatric benefit. Slow titration can make the transition easier.
A psychiatrist usually assesses more than symptom intensity. Sleep, concentration, work performance, bowel function, blood pressure, pulse, suicidal thinking, panic frequency, compulsive rituals, and medication adherence all contribute to the treatment decision.
For OCD, doctors commonly track time spent on rituals and the ability to resist compulsions rather than relying only on a general mood score. A modest reduction in ritual time may be clinically meaningful even when intrusive thoughts have not disappeared.
NICE guidance supports close observation during treatment changes, especially where mood, behaviour, or suicidality may shift [5]. A physician may also consider an electrocardiogram when cardiac history, high doses, older age, or QT-prolonging medicines create additional risk.
Pregnancy and breastfeeding require an individual assessment of clomipramine exposure, maternal symptoms, and possible infant effects. Health Canada product information describes the need to weigh treatment benefits against newborn adaptation symptoms and breast milk exposure. Guidance available in 2026 continues to support shared clinical assessment rather than an automatic rule for every patient. Abrupt discontinuation can also cause problems, so stopping or changing treatment should follow a planned medical decision. The plan should be reviewed if maternal symptoms or infant concerns change.
A current monoamine oxidase inhibitor treatment is a clear contraindication because the combination can produce severe serotonin toxicity and dangerous cardiovascular reactions. A serious conduction abnormality, recent myocardial infarction, uncontrolled seizure disorder, or untreated narrow-angle glaucoma may also rule out treatment. The FDA prescribing information (2018) identifies these risks within its contraindications and warnings. A medical history review should occur before the first dose, especially when fainting, seizures, or cardiac disease has occurred.
Tablet handling depends on the specific formulation and the intended dosing schedule. A tablet should not be crushed or chewed unless the prescriber or dispensing pharmacist has confirmed that this is suitable, because altered handling can affect swallowing, tolerability, or release characteristics. Health Canada information (2020) for clomipramine supports using the supplied oral form according to its authorized administration instructions. If swallowing is difficult, the prescriber can select an appropriate strategy rather than having the patient alter the tablet independently.
Older adults may receive clomipramine, but treatment generally requires a lower starting approach and closer observation. The risks of confusion, falls, constipation, urinary retention, low blood pressure, heart rhythm changes, and low sodium can increase with age and multiple medicines. The WHO’s medication-safety resources (2019) support regular review of anticholinergic burden and drug interactions. New dizziness, confusion, fainting, or difficulty urinating deserves prompt medical attention.
A single dose does not provide an immediate cure for OCD, depression, or panic disorder. Clomipramine and its active metabolite remain in the body for a prolonged period, so regular dosing supports a steadier exposure than occasional use. The FDA label (2018) describes pharmacokinetic persistence that helps explain why clinicians adjust doses gradually and avoid rapid changes. Symptom improvement develops over repeated doses and may take several weeks, depending on the condition and the individual response.
Urgent assessment is needed for fainting, severe palpitations, chest pain, seizure, severe confusion, high fever with rigidity or tremor, suicidal intent, mania, facial swelling, breathing difficulty, or sudden eye pain with blurred vision and halos. These symptoms can indicate a serious cardiac, neurological, allergic, serotonergic, or eye-pressure reaction. NICE safety guidance (2022) for antidepressant treatment supports prompt review when suicidal thinking or major behavioural change develops. Do not take another dose while awaiting urgent instructions if a severe reaction is suspected, unless emergency clinicians direct otherwise.
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
I used Anafranil for OCD and noticed that the intrusive thoughts became less dominant after several weeks. I still had to work on the compulsions, but I could get through the morning without repeating the same checks as often. I was satisfied with the change because it made ordinary routines manageable again.
Anafranil gradually reduced the panic episodes that had been interrupting my sleep. The improvement was slow, and I judged it by the number of attacks over each week rather than expecting a sudden change after one tablet. After a few weeks, I felt more confident leaving home and was pleased with the result.
My mood and concentration improved steadily while taking Anafranil. Work required less effort, and I stopped spending so much time stuck on repetitive thoughts. The benefit became clear over time rather than on a particular day, which made the treatment feel more realistic.
Anafranil helped reduce the frequency of my panic attacks, but the first part of treatment was difficult because I felt sleepy and had a dry mouth. The benefit was only partial, so I discussed the balance with my doctor instead of stopping on my own. It helped, though I needed to decide whether the side effects fit my routine.
